Business Context and Reporting Period
The filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020; the request metadata identifies Spyre Therapeutics, Inc., but the source document names Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE). Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics and had not generated product revenue or achieved profitability.
Key programs included pegzilarginase in a global Phase 3 PEACE trial for Arginase 1 Deficiency, ACN00177 in preparation for a Phase 1/2 Homocystinuria trial, and the AEB5100 cystinuria program.
Financial Highlights
| Metric | Three months ended March 31, 2020 | Three months ended March 31, 2019 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $14.6 million | $14.4 million |
| General and administrative expense | $4.5 million | $3.3 million |
| Total operating expenses | $19.0 million | $17.7 million |
| Interest income | $0.3 million | $0.5 million |
| Net loss | $18.7 million | $17.2 million |
| Basic and diluted loss per share | $0.57 | $0.59 |
| Net cash used in operating activities | $21.7 million | $15.8 million |
There was no meaningful revenue or operating margin because the company remained pre-commercial and loss-making. Comprehensive loss was $18.9 million in 2020 versus $17.1 million in 2019, including a $0.2 million unrealized loss on marketable securities in 2020.
Balance Sheet, Liquidity and Capital Resources
- Cash and cash equivalents were $12.6 million at March 31, 2020, compared with $19.3 million at December 31, 2019.
- Marketable securities were $36.4 million, down from $52.7 million; restricted cash was $1.5 million.
- Total cash, cash equivalents, marketable securities and restricted cash were approximately $50.5 million.
- Working capital was $37.1 million and the accumulated deficit was $213.8 million.
- The company reported no debt or credit facility. Lease obligations totaled $9.2 million, including $9.1 million of operating lease commitments.
- Cash, cash equivalents and restricted cash declined by $6.7 million during the quarter. Operating cash use was partly offset by $14.8 million of investing cash inflow, primarily marketable-security maturities.
- Management stated that available resources, together with approximately $129.6 million of net proceeds from an April 2020 public offering, were expected to fund operations through 2022, although additional financing would be needed to execute all planned development activities.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 1% to $14.6 million. Higher manufacturing, nonclinical and personnel costs were largely offset by lower clinical-development costs following completion or enrollment milestones in earlier studies.
- General and administrative expense increased 36% to $4.5 million, primarily due to additional personnel, commercial-preparation activities and office-space costs.
- Total operating expenses rose 8% and net loss increased 9% to $18.7 million.
- Operating cash burn increased by $5.9 million, or approximately 37%, primarily reflecting the higher loss and advance manufacturing payments.
- Weighted-average shares increased to 33.1 million from 29.0 million, while reported loss per share improved slightly due to share-count dilution.
- Stock-based compensation increased to $1.3 million from $1.1 million.
Guidance, Outlook, Risks and Unusual Items
- COVID-19 caused all Phase 3 PEACE sites to suspend screening for additional enrollment, and some patients missed dosing appointments. Management expected enrollment completion in the third quarter of 2020 and topline data in the first quarter of 2021, but acknowledged substantial uncertainty.
- The company was preparing to initiate the ACN00177 Phase 1/2 trial in the second quarter of 2020 following U.K. CTA approval; timing depended on site readiness and COVID-19 conditions.
- Management reported no significant supply-chain impact as of the filing date and stated that clinical-trial supply was sufficient, but identified risks involving enrollment, dosing, site operations, hospital capacity, regulators, suppliers and manufacturers.
- The company expected continued operating losses and increasing expenses as it advanced clinical trials, manufacturing, commercialization preparation, intellectual property and staffing.
- In April 2020, Aeglea sold 15.4 million common shares and pre-funded warrants for 13.6 million shares, generating approximately $129.6 million of net proceeds. It also established a $60.0 million at-the-market program. These transactions could materially dilute existing shareholders.
- License obligations to the University of Texas included up to $6.4 million of development and regulatory milestone payments, low single-digit royalties on worldwide net sales and sublicense revenue sharing.
- The company disclosed no material pending legal proceedings, no off-balance-sheet arrangements and no impairments of long-lived assets or marketable securities.
- Disclosure controls and procedures were deemed effective at a reasonable-assurance level, with no material changes in internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the source filing is for Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Verify the April 2020 financing proceeds, share and pre-funded-warrant counts, and the resulting potential dilution.
- Assess whether the stated cash runway through 2022 remains supported by actual spending, trial costs and subsequent clinical developments.
- Track COVID-19-related enrollment and dosing disruptions in the PEACE trial and whether the projected third-quarter 2020 enrollment and first-quarter 2021 data timelines were achieved.
- Evaluate the regulatory, safety and efficacy prospects for pegzilarginase and the ACN00177 development timetable.
- Review future capital requirements, including the absence of product revenue, continuing losses, lease commitments, license milestones and possible additional equity financing.